This Week in Obesity Medicine A Phase 2 trial of petrelintide, a once-weekly amylin drug, showed up to about 10% weight loss at 42 weeks with modest nausea (about 20% vs 6% on placebo). It is not approved, has not been compared directly with GLP-1 drugs, and is in Phase 3. Novo Nordisk’s first real-world
